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Abstract
Objective: To synthesize the available evidence and state of the art of economic evaluations 
which evaluate the use of memantine, whether alone or combined with donepezil, for 
moderate to severe Alzheimers disease (AD), focusing on the analytical decision models 
built. Method: The electronic databases MEDLINE, EMBASE, NHS EED, CEA 
Registry and LILACS were searched for references. After duplicates were removed, two 
independent reviewers evaluated the titles and abstracts and subsequently the full texts. 
The Drummond M. tool was used to evaluate the quality of the studies. Results: After 
the application of the eligibility criteria, twelve complete economic evaluations were 
included. One evaluation was a clinical trial, two involved simulations and nine used 
Markov models. The main outcome measure adopted was dominated by cost per quality 
adjusted life year (QALY). The use of memantine was considered cost-effective and 
dominant in eight studies; while in a single study, its use was dominated when compared 
to donepezil for moderate AD. Sensitivity analyzes were systematically performed, 
with robust results. The quality assessment indicated that the methodological quality 
of the studies was good. Conclusion: Although there is some controversy regarding the 
benefits derived from the use of memantine, whether combined or not with donepezil, 
the evidence collected suggests that it is cost-effective in the countries where the studies 
were performed. However, local economic studies need to be performed, given the 
significant variability derived from the different parameters adopted in the evaluations.
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INTRODUC TION
Alzheimers Disease (AD) represents a serious 
public health problem, as it is the main cause of 
cognitive decline and dementia in adults, especially 
older adults. Its diagnosis is primarily clinical, based 
on the application of standardized criteria, and 
it progresses with damage to memory and other 
cognitive and behavioral functions1.
AD affects around 25 million people around the 
world2 and projections suggest that this total may 
reach 100 million by 20503. In addition, a meta-
analysis published in 2013 reports that the prevalence 
of dementias, standardized by age, varies between 5% 
and 7% in those aged 60 or older, and is higher in less 
developed countries, most of all in Latin America4.
It is estimated that, in 2030, the elderly population 
in Brazil will reach approximately 41.6 million and 
that by 2060, one in every three Brazilians will be 
older than 605. Brazilian studies have indicated a 
prevalence of dementia in the population aged over 
65 of 7.1%, with AD responsible for more than 44% 
of cases6.
There is currently no cure for AD and the impact 
of the illness on patients and caregivers leads to 
political pressure to ensure that all the possible 
treatments are widely available. In addition, there 
are limited options in terms of interventions during 
the course of the disease, which include two main 
groups of drugs.
Acetylcholinesterase inhibitors represent the first 
line of treatment of mild to moderate AD. Their use 
is based on the reduction of the cholinergic deficit, 
through the inhibition of the enzymes that degrade 
acetylcholine, increasing its synaptic availability and 
improving cognitive symptoms1. Memantine is a 
non-competitive NMDA (N-Methyl-D-Aspartate) 
glutamate receptor antagonist. It is the only drug in 
its class used in humans and is approved by the Food 
and Drug Administration, the European Medicines 
Agency and the National Health Surveillance Agency 
for the treatment of moderate to severe AD7,8.
Studies on the efficacy of memantine in severe 
AD have produced controversial results. The drugs 
ability to delay symptom worsening and improve 
the functional capacity of patients with moderate to 
severe AD was originally demonstrated in two phase 
III randomized controlled clinical trials (RCCT)9,10, 
both with a very short follow-up of 24 weeks. 
Other trials, however, have failed to show such 
favorable results in measures of cognitive function 
and activities of daily living11. Meta-analyzes 
examining the efficacy of memantine used alone or 
in combination with anticolinesterase inhibitors have 
found that improvements in cognitive functions and 
activities of daily living in patients with moderate to 
severe AD when present were systematically small 
in scale12-14. The evidence is also conflicting in terms 
of behavioral and neuropsychiatric symptoms15. In 
contrast, although usually mild to moderate, patients 
on memantine may experience headaches, dizziness, 
fatigue, mental confusion, and hallucinations10. Some 
other aspects that undermine the available evidence 
on the efficacy of memantine are worth mentioning: 
some RCCTs had small sample sizes, significant 
follow-up losses, received direct funding, or had 
authors who declared having received different types 
of funding from the pharmaceutical industry, and, 
therefore, potential conflicts of interest could  not 
be excluded16.
Due to the transient efficacy of AD treatment 
drugs, the progression to functional dependence 
continues even with their use17. In addition, they are 
often difficult to use due to their adverse events, 
such as hypertension, drowsiness and central 
nervous system-related disorders, and interactions 
with other drugs. 
Considering the harm-benef it rat io as 
unfavorable, with low efficacy results and potentially 
significant adverse events in frequency and severity, 
the French Ministry of Health decided that as of 
August 2018 anticholinesterases and memantine 
would no longer be reimbursed by the national 
health insurance system. At the end of 2016, the 
Pharmacoeconomic Transparency Committee, 
which makes recommendations on public drug 
reimbursement in France, concluded that these 
drugs did not bring sufficient clinical benefits and 
called for their exclusion from the list of publicly 
provided drugs in France, which only became 
official following the Haute Autorité de Santé report 
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in May 201818,19. The drug, however, is still present 
in clinical treatment protocols and is reimbursed in 
other countries, such as through Medicare in the 
US, the UK and Australia20.
In Brazil, anticholinesterases have been available 
in the Unified Health System (or SUS) since 2002, 
restricted to patients with mild to moderate forms 
of the disease21. Memantine, however, was only 
incorporated within the SUS for the treatment of 
moderate and severe AD in 20177. Even before that, 
however, it was bought by the Ministry of Health 
(MoH), with a total purchase of approximately 
33,000 10mg tablets between 2010 and 2014, to 
meet judicial orders22.
The burden of disease and the costs associated 
with AD, population aging, and the lack of disease-
modifying treatment options raise concerns about the 
efficient use of resources. While current legislation 
in Brazil requires comparative cost-effectiveness 
evidence for the incorporation of a new technology 
into the SUS23, economic evaluation studies have 
not been carried out by the Ministry of Health, with 
their introduction into the system being justified by 
clinical data and the drugs incorporation into the 
payment systems of other countries7.
Given the uncertainties in literature, the present 
study aimed to synthesize the evidence available in 
economic studies regarding the use of memantine, 
whether alone or combined with donepezil, to treat 
moderate to severe AD, focusing on the analytical 
decision models used in these evaluations.
METHOD
This systematic review was reported in accordance 
with the Preferred Reporting Items for Systematic 
Reviews and Meta-analysis (PRISMA)24 guidelines 
and registered with the PROSPERO International 
Prospective Register of Systematic Reviews under 
No. CRD42017076469, in October 2017.
Study identif ication and search strategy
The MEDLINE, EMBASE, and LILACS 
bibliographic databases, as well as the Cochrane 
Collaboration and specific bases for economic studies 
 the NHS Economic Evaluation Database (NHS 
EED), the Database of Abstracts of Reviews of 
Effects (DARE) and the Cost-Effectiveness Analysis 
(CEA) Registry - were used to search for studies 
published up to March 2017. 
Search strategies were developed for each database 
based on specific descriptors, combined with the 
Boolean operators for AD and the drugs of interest 
(donepezil and memantine), using specific filters 
for economic studies. Search strategies specific to 
each database can be obtained by correspondence 
with the authors. 
There was no restriction on publication period 
or language in the search. Narrative and systematic 
reviews of economic studies on the subject were 
examined for cross-references that might not 
otherwise have been identified.
References identified in electronic databases were 
managed using the ENDNOTE® software (version 
X4) for the elimination of duplicates.
Study selection
The articles were selected in two stages (titles and 
abstracts and, later, the full text), by two reviewers 
(IAGO and ANB), with disagreements resolved by 
consensus or, when necessary, through consultation 
with a third reviewer (RC).
To be included, studies were required to meet 
the following eligibility criteria: either primary 
studies (economic assessments conducted through 
observational studies and randomized controlled 
trials) or modeling studies related to the use of 
memantine, whether alone or in combination with 
donepezil, in adult patients diagnosed with moderate 
to severe AD, with disease severity determined 
by a specified assessment scale. Only complete 
economic assessments (cost-effectiveness analysis, 
cost-utility analysis or cost-benefit analysis) with 
the clear identification of comparators (placebo, 
no specific treatment, galantamine, rivastigmine 
or donepezil anticholinesterases or other types of 
non-pharmacological treatment) and measures of 
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outcome, such as cost per year of life gained, cost per 
quality adjusted life year (QALY) and cost per time 
spent in a non-dependent state, were considered. All 
studies written in English, Portuguese and Spanish 
were included. 
Letters, editorials, narrative reviews, partial 
economic assessments, and studies that did not 
contain explicit information on the methods and 
criteria defined above were excluded.
Methodological Qualit y Assessment
The quality assessment of the included economic 
studies was also performed by two independent 
reviewers (IAGO and RES), with disagreements 
resolved as described above. 
The tool developed by Drummond M.25 was used. 
It presents 35 evaluation items, distributed in three 
sections: aspects of study design; sources and quality 
of the collected data; data analysis and interpretation 
of results. Six additional items were introduced: data 
related to the presence of subgroup analysis, study 
limitations, potential for generalization of results, 
declarations of conflict of interest and study funding.
Each item was judged as yes, no, not clear, or 
not-applicable.
Data ex traction
The relevant data were independently extracted 
by two reviewers and recorded in a standardized 
electronic form built on EPIDATA software, with 
disagreements resolved by a third reviewer.
Data were extracted related to (i) study 
identif ication; (i i) general characteristics of 
economic assessments (type and design of study; 
country; characteristics of population studied; 
type of intervention and comparator; measure of 
effectiveness adopted and data source; types and 
details of included costs; currency and year of 
reference; Alzheimers disease progression model; 
outcomes; presence of cost-effectiveness threshold) 
(iii) general characteristics of the analytical decision 
models used (perspective, time horizon, main 
health outcomes, analytical approach, discount rate 
application, sensitivity analysis), as well as (iv) main 
model conclusions and limitations.
The collected data were analyzed descriptively 
using Microsoft Excel 2010. For the nominal data, 
numbers and percentages are provided, while 
median and ranges are used for the ordinal data. 
No summary measures related to the incremental 
cost-effectiveness measures, which are not usually 
recommended in systematic reviews of economic 
analyzes, were calculated, given the methodological, 
population and interventions predictable differences 
between studies, which may generate significant 
heterogeneity of results26.
The characteristics and results of the included 
studies were summarized using tables, complemented 
by a narrative summary that sought to compare and 
evaluate the methods used and the main results 
between the studies. 
RESULTS
A total of 1,171 references were identified in the 
bibliographic databases searched. After eliminating 
167 duplicate records, 1,004 abstracts were examined 
and 63 full-text articles were evaluated. Of these, 12 
economic assessments met the eligibility criteria27-38 
and were included in the review (Figure 1).
There was considerable variation in the countries 
where the evaluations were conducted, with five 
studies carried out in the United Kingdom. More 
than half of the studies were published from 2010 
onwards. Data on the age of the simulated populations 
varied considerably, but 83.3% considered the study 
population to be 60 years or older (Table 1). 
Cost-utility studies that measured outcomes in 
terms of cost per QALY gained were the predominant 
type of economic assessment (75%), and there were 
only two studies35,38, both cost-effectiveness studies, 
in which results were expressed only in terms of cost 
per year of life with independence gained. Eleven 
studies included populations with moderate-severe 
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EE: Economic evaluations; AD: Alzheimers Disease; ICER: Incremental cost-effectiveness ratio.
Figure 1. Flowchart of the search and selection process of studies included in the systematic review. 
AD in their analysis. Six studies used more than one 
analytical perspective to assess costs and benefits; 
the perspective of society, in which all costs were 
computed, including those incurred by caregivers 
or due to loss of productivity of patients and their 
families, was adopted in seven studies (58.3%) while 
the health system perspective, in which only the costs 
incurred by the health care funder are considered, 
was used in seven (58.3%) studies, and social security 
costs were considered in three.
The main source of information on drug efficacy 
measures used to feed the models was previously 
published controlled clinical trials (75%). 
As can be seen in Table 2, which summarizes the 
main characteristics of the models used in economic 
evaluations, a single study was conducted through a 
clinical trial (piggyback evaluation) and did not use 
modeling in its construction27, while nine economic 
evaluations (75%) used Markovs approach as their 
analytical model. 
The main measure of cost-effect iveness 
outcome was the quality-adjusted life year (QALY). 
Intermediate outcomes, such as cost per year or 
period of independence and cost per year without 
patient institutionalization, were used in three 
studies33,35,38 (Chart 2). 
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Chart 1. General characteristics of economic assessment studies included in the systematic review.
Author, year
Country /
Currency (year*)
Type of 
Economic 
Evaluation 
and Target 
Population
Perspective of 
Analysis
Intervention 
Examined Versus 
Comparator Used in 
Economic Evaluation
/Effectiveness data 
source type
Costs included in economic assessment 
studies
Knapp et al., 
201627
UK /  (2013/14)
ACU
Moderate/
severe AD
Health System 
Society
MEMAN vs PL
MEMAN + DON vs 
DON/RCCT
Direct: Drugs, Consultations, 
Hospitalization, Caregiver / Indirect  
Hyde et al., 
201328
UK / £ (2009)
ACU
Moderate/
severe AD
Health System MEMAN vs absence 
of treatment***
(Systematic Review)
Direct: Drugs, appointments, 
hospitalization, other health 
professionals
Rive et al., 201229 
Norway /  
(2009)
ACU
Moderate/
severe AD
Society
Health System
MEMAN vs Ach**
(Metanalysis)
Direct: Drugs, appointments, tests, 
hospitalization, caregiver, other health 
professionals / Indirect 
Hartz et al., 
201230
Germany / 
(2011)
ACU
Moderate AD
Society
Social Security
MEMAN vs DON
(RCCT)
Direct: Drugs, appointments, exams, 
hospitalization, caregiver, other health 
professionals, / Indirect: 
Bond et al., 
201231
UK /£ (2009)
ACU
Moderate/
severe AD
Health System MEMAN vs absence 
of treatment***
(Systematic review)
Direct: Drugs, consultations, 
hospitalization, caregiver, other health 
professionals, institutionalization costs, 
other support measures 
Rive et al., 201032
UK / £ 
(2008/2009)
ACU
Moderate/
severe AD
Health System
Social Security
MEMAN vs Ach**
RCCT
Direct: Drugs, hospitalization, other 
health professionals 
Gagnon et al., 
200733
Canada / CAD$ 
(2005)
ACU
Moderate/
severe AD
Society MEMAN vs absence 
of tto***
RCCT
Direct: Drugs, consultations, 
hospitalization, outpatient care, other 
health professionals, institutionalization 
costs, caregiver / Indirect : 
Weyker et al., 
200734
USA / US$ 
(2005)
ACU
Moderate/
severe AD
Society MEMAN + DON vs 
DON
RCCT
Direct: Drugs, consultations, 
hospitalization, institutionalization 
costs, outpatient appointments / 
Indirect  
Antonanzas et 
al., 200635 
Spain /  (2005)
ACE
Moderate/
severe AD
Society MEMAN vs absence 
of treatment***
RCCT
Direct: Medicines, Consultations, 
Hospitalization / Indirect  
Jonsson et al., 
200536
Sweden / SEK 
(2004)
ACU
Moderate/
severe AD
Health system MEMAN vs PL
RCCT
Direct: Drugs, consultations, 
hospitalization, health professionals.
François et al., 
200437
Finland /  
(2001)
ACE
Moderate/
severe AD
Society MEMAN vs PL
RCCT
Direct: Drugs, consultations, 
hospitalization, caregiver, 
institutionalization costs, other health 
professionals / Indirect 
Jones et al., 
200438
UK / £ (2003)
ACU
Moderate/
severe AD
Health system
Social security
MEMAN vs PL
RCCT
Direct: Drugs, consultations, 
hospitalization, outpatient care, other 
health professionals, institutionalization 
costs
Ach: Cholinesterase inhibtor, ACE: cost-effectiveness, ACU: cost-utility, AD: Alzheimers Disease; DON: donepezil, RCCT: Randomized 
Clinical Controlled Trial; USA: United States; MEMAN: memantine, PL: placebo; *Year in which costs were reported, **Author does not 
discriminate cholinesterase chibinito; *** absence of specific pharmacological treatment;   Indirect costs involving costs of informal workers
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Chart 2. General characteristics of the analytical decision model structures of the studies included in the systematic 
review.
Study / 
Year
Time horizon Main Outcome /
Measures
Analytical Approach:
Model, States/Cycle Length
Discount rate 
(%)
Costs / 
Benefits
Hyde et al., 
201328
20 years Cost/QALY Markov
3 states (pre-institutionalized, 
institutionalized and dead)/ 12 months
No 
Information
Rive et al., 
201229
5 years Cost/QALY Markov
3 states (pre-institutionalized, 
institutionalized and dead)/ 1 month
3 / 3
Hartz et al., 
201230
10 years Cost/QALY Discrete-event simulation 3 / 3
Bond et al., 
201231
20 years Cost/QALY Markov
3 states (pre-institutionalized, 
institutionalized and dead)/ 12 months
3.5 / 1.5
Rive et al., 
201032
5 years Cost/QALY Markov
3 states (pre-institutionalized, 
institutionalized and dead)/ 1 month
3.5 / 3.5
Gagnon et 
al., 200733
2 years Cost/QALY
Cost/year of 
independence
Markov
5 states (combination of severity and 
independence and dead stages) / 6 months
5 / 5
Weyker et 
al., 200734
6 months / 1 
year / 1.5 years 
/ 2 years / 
Lifetime
Cost/QALY Discrete-event simulation 3 / 3
Antonanzas 
et al., 
200635
2 years Cost/year of 
independence
Markov
6 states (combination of severity and 
independence and dead stage) / 6 months
6 / 6
Jonsson, 
200536
5 years Cost/QALY Markov
13 states (combination of three variables: 
severity, independence, institutionalization 
status, and dead) / 6 months
3 / 3
François et 
al., 200437
5 years Cost/year of 
independence gained
Cost/year without 
institutionalization
Markov 
13 states (combination of severity, 
independence, institutionalization status, and 
dead) / 6 months
5 / 5
Jones et al., 
200438
2 years Cost/QALY Markov
13 states (combination of three variables: 
severity, independence, institutionalization 
status, and dead) / 6 months
3.5 / 3.5
QALY: Quality-adjusted life-year;
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Eight studies (66.6%) employed in its analysis a 
time horizon of five years or more, two had a time 
horizon of 20 years28,31 and one used lifetime34. 
The number of Markov states and the duration 
of cycles varied between publications. Four studies 
(33.3%) considered only three health states (pre-
institutionalized, institutionalized and dead)28,29,31,32. 
The main study designs used to investigate the 
progression of AD and the likelihood of change in 
health status were clinical trials and observational 
studies from population-based registries.
The scales used for the clinical evaluation of AD 
and the domains considered differed greatly between 
studies. The cognitive approach and measures related 
to activities of daily living, in addition to behavior, 
were the main competences included. 
Regarding the main findings of the economic 
assessments included, the results of the use of 
memantine was considered cost-effective and 
dominant, i.e., less costly and more effective than 
its comparator, in nine studies (75%), as shown in 
Chart 3. In one study only28, memantine was not 
cost-effective when compared to donepezil in the 
moderate AD population, defined by the MMSE 
VFRUHVRIDQG7DEOH
A sensitivity analysis to examine the uncertainty 
regarding the parameters and structure of the models 
was included in all studies, with deterministic analyses 
being the most used (66.6%); while extreme scenario 
analyses were included in two studies33,36. 
The methodological quality of the included 
studies was considered good (Figure 2). The worst 
quality items were the justifications for choosing 
the discount rate adopted, details of the statistical 
methods and the disaggregated presentation of 
results. All the manuscripts presented arguments 
regarding the limitations of their study. In addition, 
80% declared a conflict of interest and funding in 
their publications. Most manuscripts were funded 
by industry (75%).
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Chart 3. Main results of economic assessments and uncertainty analyzes
Author Main results Sensitivity Analysis
Knapp et al., 
201627
ICER*/ HS: MEMAN vs dominant PL / 
MEMAN +DON vs DON cost-effective; Soc. 
MEMAN+DON vs DON non-cost-effective 
Acceptability C.: Chance 95% MEMAN cost-
effective vs3/ZLWKWKUHVKROGRIȮDQGRI
55% of MEMAN + DON vs DON cost-effective 
with same threshold 
Hyde et al., 
201328
ICER £32,100/QALY / MEMAN cost-effective 
vs no specified treatment
Acceptability C.: Chance of 38% MEMAN cost-
effective vs no treatment with threshold of 30.000
Rive et al., 
201229
Negative ICER ** / MEMAN dominant vs 
Ach***
Deterministic: MEMAN dominant vs Ach***
Probabilistic: Chance >98% of MEMAN being 
cost-effective
Hartz et al., 
201230
MEMAN non-cost-effective and dominated by 
DON
ƅFRVWV'21½ƅ4$/<
Deterministic: DON dominant vs MEMAN in all 
simulations
Probabilistic: Chance >70% of DON dominating 
MEMAN
Acceptability C.: Chance >90% of DON cost-
effective with threshold of 10,000
Bond et al., 
201231
ICER*£32,100/QALY / MEMAN cost-effective 
vs no specified treatment
Deterministic: MEMAN cost-effective; MEMAN 
effectiveness alters ICER
Acceptability C.: Chance 38% MEMAN cost-
effective with threshold of £30,000
Rive et al., 
201032
ICER negative** / MEMAN cost-effective vs 
Ach***
ƅFRVWVƅ4$/<
Deterministic: MEMAN dominant vs Ach***
Probabilistic: Chance >99% MEMAN being cost-
effective
Acceptability C.: Chance >98% MEMAN cost-
effective with threshold of 20,000 
Gagnon et 
al., 200733
ICER negative** / MEMAN cost-effective vs no 
treatment
ƅFRVWV&$'ƅ4$/<ƅ\HDUV
without complete dependence: 0.09
Deterministic: MEMAN dominant vs no treatment
Probabilistic: MEMAN cost-neutral in 83.3% 
Acceptability C.: Chance 89.5% MEMAN cost-
effective with threshold of 20,000
Weyker et 
al., 200734
ICER*: TH of 6m: 3.475 / TH of 12m: 382 / 
TH de 18m: -5.102 / TH entire life: -US$8,880 / 
MEMAN + DON is cost-effective vs DON
Deterministic: MEMAN cost-effective and 
dominant vs DON
Antonanzas 
et al., 200635
ICER negative** / MEMAN cost-effective vs no 
treatment
ƅFRVWV½ƅ\HDUVLQGHSHQGHQFHJDLQHG
0.202
Acceptability C.: Chance >98% MEMAN cost-
effective vs PL with threshold of 30,000
Jonsson, 
200536
ICER negative** /MEMAN cost-effective vs PL
ƅFRVWV6(.ƅ4$/<
Deterministic: MEMAN dominant vs PL
Extreme scenario analysis: MEMAN dominant
François et 
al., 200437
ICER negative** / MEMAN cost-effective vs PL
ƅFRVWV½ƅ\HDUVRILQGHSHQGHQFH
Probabilistic: Chance >93% MEMAN vs PL cost-
effective and dominant
Acceptability C.: Chance >99% MEMAN cost-
effective with threshold of 30,000
Jones et al., 
200438
ICER negative** / MEMAN cost-effective vs PL
ƅFRVWVƅ4$/<
Deterministic univariate: MEMAN cost-effective vs 
PL in all scenarios
Acceptability C.: Acceptability Curve; DON: Donepezil; MEMAN: Memantine; PL: Placebo; TH: Time Horizon; QALY: Quality-adjusted 
OLIH\HDU,&(5,QFUHPHQWDOFRVWHIIHFWLYHQHVVUDWLR+6+HDOWKFDUH6\VWHP6RF6RFLHW\ƅ'LIIHUHQFHYVYHUVXV; *ICER: Incremental cost-
effectiveness ratio; Negative ICER **: use of intervention represents resource savings compared with comparator; Ach***: Non-specified inhibitors
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DISCUSSION
The increase in health-related costs in a scenario 
of limited resources, as well as the growing 
prevalence of Alzheimers disease associated with 
population aging, mean it is imperative to examine 
the relationship between costs and clinical benefits 
the drugs used in their treatment, especially when 
evidence of the efficacy of therapy isnt strong and 
the benefits are considered insufficient. 
A systematic review of the risk-benefit of inhibitors 
and memantine use in AD states that its benefits are 
marginal and short-termed, indicating that it should 
be used cautiously in the elderly population, where 
side effects may be more significant, especially with 
inhibitors of the drugs17. Some health systems do 
not include or have withdrawn memantine funding 
for the treatment of moderate to severe stages of 
disease18,19. Others restrict this funding to fixed 
time periods (eg, one year), during which users 
EE: Economic Evaluations; CI: Confidence Intervals
Figure 2. Assessment of methodological quality of economic evaluation studies included. 
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are periodically reassessed, with the suspension of 
coverage if there is evidence of disease progression 
supported by the application of certain scales such 
as the Mini-Mental State Exam (MMSE) and the 
Clinical Dementia Rating (CDR)39.
Considering the incremental cost-effectiveness 
ratios and cost-effectiveness thresholds defined 
in each country, the results showed that the use 
of memantine for moderate to severe AD was 
considered cost-effective in most studies, being the 
dominant therapeutic strategy in eleven articles, 
that is, less costly and with better health outcomes. 
Sensitivity analyzes concerning the variation of a 
large number of parameters reinforce the fact that 
these results were robust, that is, they remained 
favorable to memantine. 
It should be noted, however, that all studies 
were conducted in developed countries and mostly 
applied the societal perspective, computing costs that 
included caregiver time, costs incurred by families 
and productivity losses associated disease, wheter 
by patients or family members.
The incremental cost-effectiveness ratios resulting 
from the analyzes varied widely. This variability 
possibly resulted from aspects related to study 
design, the perspective adopted and the assumptions 
considered, resulting in limitations related to the 
comparability between studies. 
The results are consistent with some reviews 
already available on the subject. In 2018, a systematic 
review published by Ebrahem and Oremus16 on 
economic assessments related to the treatment of AD 
identified 14 studies related to the use of memantine 
alone or combined with anticholinesterases, with 
93.7% of the studies also finding that memantine 
was cost-effective.
A single study included in the present review 
concluded that the strategy of using memantine 
alone was dominated by donepezil for moderate AD, 
or in other words, the inhibitors had comparatively 
lower costs and better health outcomes30. Sensitivity 
analyzes reinforced the robustness of these results, 
being favorable to donepezil based on variations 
in the parameters, with the acceptability curve 
showing a greater than 90% chance of inhibitor 
being cost-effective at a threshold as low as 
10,000.00 (2011 figures). 
The study by Hartz et al.30, conducted in Germany 
with a ten-year time horizon, used discrete-event 
simulation to capture, from the societal perspective, 
the costs and effects of treatment with respect to 
activities of daily living, improvements in function 
measured by MMSE and in the neuropsychiatric 
inventory. Unlike the other evaluations, the target 
population considered had moderate AD, the clinical 
stage of the disease in which the effects of memantine 
in isolation remain controversial40.
The included studies that examined memantine 
in combination with donepezil also indicated 
divergent cost-effectiveness results between studies, 
depending on the reference population27,34. The study 
by Knapp et al.27, an economic evaluation performed 
in parallel with a controlled clinical trial published 
in 2016, showed that the memantine-donepezil 
combination was not cost-effective compared to 
donepezil alone for moderate disease23. The study 
by Weyker et al.34, meanwhile, conducted in the US 
using discrete-event simulation, showed that this 
association was cost-effective for moderate and 
severe AD, considering time horizons greater than 
six months. In addition to examining diverse patient 
populations, the study designs were also distinct, 
which may have contributed to the difference in 
outcomes observed.
Markovs approach was the main type of modeling 
employed in the economic assessments examined 
(75%). The use of Markov chains is frequently 
recommended for modelling chronic diseases, where 
individuals move between different stages of the 
disease over time, reflecting their natural history41.
The simulated time horizons in the studies 
ranged from two years to lifetime, with most having 
horizons of five years or more. Considering that AD 
has a median survival period of 8.3 years in patients 
diagnosed aged 65 and over42, the chosen horizons 
mostly contemplate the life expectancy of these 
patients and can adequately capture the most relevant 
costs and benefits expected from the treatments used.
The cognitive domain is a relevant outcome in the 
natural course of the Alzheimers disease progression 
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process and should be adopted in the modeling of 
this disease. However, modeling should also adopt 
domains other than the cognitive in order to consider 
the complexity of this disorder. 
Literature suggests that modeling including 
aspects related to function, level of patients 
dependence on a caregiver and quality of life may 
more accurately reflect the progression of AD43. 
Clinical trials, commonly used as a data source in the 
economic evaluations found, are often insufficient 
and too short to evaluate such results, for which 
economic health models that combine trial data 
with real-world evidence are particularly useful44. 
The vast majority of the evaluations present in this 
review used, as an outcome of the cost-effectiveness 
of the intervention, quality-adjusted life years, 
whether alone or combined with other dimensions. 
QALY is a multidimensional concept whose use is 
particularly important in chronic conditions, and 
especially when the results of the intervention affect 
survival less and the domains of relationships and 
living more (cognition, mood, behavior, functionality 
and the ability to live longer without requiring special 
care or institutionalization), as observed in AD45. 
However, some studies suggest that QALY may not 
be fully accurate for the evaluation of individuals 
living with AD, as it is often caregivers, and non-
patients, who provide proxy measures46. 
There is a relative scarcity of data related to the use 
of drugs such as memantine and donepezil and their 
effects on delaying institutionalization47. In addition, 
the reasons leading to the institutionalization of AD 
patients are multifactorial and complex, involving 
patient and caregiver characteristics, and the 
social and cultural environment. These types of 
outcomes are not usually evaluated in clinical trials, 
have significant impacts on health costs, and may 
underestimate overall cost measures, particularly 
the indirect costs of AD patient care48.
Finally, it should be mentioned that most 
evaluations assumed that the drugs did not have an 
effect on mortality, which was supported by the fact 
that symptomatic therapies generally had no effect 
on the underlying disease process, and the lack of 
evidence of such an effect from relatively short-term 
clinical trials.
Most of the evaluations used randomized 
controlled trials as a source of data on the effectiveness 
of treatment. This can set a good internal validity 
in the model construction, but has a low external 
validity, since most trials have a short duration and 
cannot add long-term treatment effects. In addition, 
the use of parameters from a clinical trial conducted 
in one country in evaluations performed in another 
may pose a problem in generalizing modeling results, 
which is further accentuated when measures are 
applied as utilities to generate QALY.
Few economic models used in the simulations 
contemplated the scope of the natural history of 
AD. There is great variability in the assumptions 
made in these studies, in their effectiveness and 
cost data sources, their utility measure calculations 
and the transparency of their models. Therefore, 
caution is advised regarding the conclusions of the 
present review. 
Finally, the number of economic evaluations 
funded by the pharmaceutical industry in which 
their drugs dominated their comparators was high, 
increasing the risk of possible publication bias.
CONCLUSIONS
Most of the economic assessments included in 
this review indicate that the use of memantine alone 
or combined with donepezil for moderate to severe 
Alzheimers disease is predominantly cost-effective in 
countries where the studies were conducted. Although 
most uncertainty analyzes confirm the robustness 
of the results presented, caution is required when 
transferring cost-effectiveness findings from one 
country to another, either because of the difficulty 
of extrapolating data costs due to different payment 
structures and systems and national incentives, or 
because considering a cost-effective strategy is closely 
related to the cost-effectiveness thresholds implicitly 
or explicitly adopted in each country. The fact that 
most evaluations are funded by industry highlights 
that studies may contain significant biases and, 
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for that reason, caution should be exercised in the 
process of interpreting these results.
Therefore, local-based analyzes should be 
performed in Brazil, paying close attention to the 
issues and limitations raised from the economic 
evaluations already performed, so that the cost-
effectiveness of memantine, whether combined or 
not with donepezil, for severe Alzheimers Disease 
is more accurately assessed.
Edited by: Ana Carolina Lima Cavaletti
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